Why Lantheus Holdings Stock Is Skyrocketing Today

Investors are cheering a proposed rule that could boost Lantheus' revenue. In the past, CMS has bundled the costs of diagnostic radiopharmaceuticals in with the payment for related nuclear medicine tests. The agency said that in some cases, this payment doesn't fully cover the cost of the associated diagnostic radiopharmaceuticals. CMS is proposing to pay for diagnostic radiopharmaceuticals with a cost greater than $630 per day separately from the nuclear medicine tests. Roughly 70% of Lantheus' total reven ...